Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01497938 · ClinicalTrials.gov registry record · Phase 3
Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature
A Phase 3 study, sponsored by Medtronic MiniMed.
- Completed
- Registry status
- Phase 3
- Development phase
- 247
- Enrollment target
NCT01497938: Completed Phase 3 study, sponsored by Medtronic MiniMed.
NCT01497938 is a Phase 3 study that has completed, run by Medtronic MiniMed. The registered enrollment target is 247 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01497938, a Phase 3 study, has completed, sponsored by Medtronic MiniMed.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 247 participants
- Enrollment target
Study Summary
Introduction: The purpose of the pivotal In Home study is to collect clinical data on the safety and efficacy of the Paradigm LGS System in the actual use environment and by the intended use population. ASPIRE is a multi-center, in home, randomized parallel adaptive study design with type 1 diabetes. The study will compare A1C and CGM based nocturnal hypoglycemic events in a treatment arm to a control arm. Arms are defined as: * Treatment Arm (LGS ON) using Paradigm® VEO™ Pump * Control Arm (NO LGS FEATURE ) using Paradigm® Revel™2.0 Pump The study's objectives are two-fold: 1. The first study objective is to demonstrate that home use of Low Glucose Suspend (LGS) is safe and is not associated with glycemic deterioration, as measured by change in A1C from baseline to end of study participation. 2. The second study objective is to demonstrate that home use of Low Glucose Suspend (LGS) is associated with reduction in nocturnal hypoglycemia when patients fail to respond. Primary Safety Endpoint: The change in A1C from randomization to the end of the treatment period will be used to demonstrate that the automatic insulin delivery suspension (LGS ON) does not result in an unacceptable worsening of glycemic control.
Primary Outcome
The first study objective is to demonstrate that home use of Low Glucose Suspend (LGS) is safe and is not associated with glycemic deterioration, as measured by change in A1C from baseline to end of study participation.
Interventions
- DEVICE Medtronic MMT-754 Veo Insulin pump testing Low Glucose Suspend (LGS) feature
- DEVICE Medtronic (NO LGS FEATURE ) using Paradigm® Revel™2.0 Pump
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 247 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-06 |
| Phase | Phase 3 |
What the finished NCT01497938 record still lists
NCT01497938 is an interventional study that assigns participants to a tested intervention. The registered 247 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 2 interventions - of which Medtronic MMT-754 Veo Insulin pump testing Low Glucose Suspend (LGS) feature is the first listed.
NCT01497938 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01497938 about?
NCT01497938 is a clinical study titled "Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature". Introduction: The purpose of the pivotal In Home study is to collect clinical data on the safety and efficacy of the Paradigm LGS System in the actual use environment and by the intended use population. ASPIRE is a multi-center, in home, randomized parallel adaptive study design with type 1 diabete...
What is the current status of trial NCT01497938?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 247 participants. The study started on 2011-12. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01497938?
The interventions under investigation include: Medtronic MMT-754 Veo Insulin pump testing Low Glucose Suspend (LGS) feature (DEVICE), Medtronic (NO LGS FEATURE ) using Paradigm® Revel™2.0 Pump (DEVICE).
Who is sponsoring clinical trial NCT01497938?
This trial is sponsored by Medtronic MiniMed, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01497938's enrollment target sits among peer trials
247 1266th of 2000 higher than 734 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04269902 · 247 participants · Phase 3
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- NCT04989803 · 247 participants · Phase 1
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
- NCT05521399 · 247 participants
Heart Transplantation - Renewal
- NCT05556824 · 247 participants · Phase 2
Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia